Citron Comments on Recent Coverage of Intrexon


Dear Readers,

In August 2015, Citron tweeted that we were buying shares of Intrexon (NYSE:$XON). Upon further due diligence we sold our Intrexon, as we found none of the company’s businesses to have any imminent viability.  We should have updated our readers, but we had received almost no correspondence on the name after our tweet.

Citron wants its readers to note that we are not long shares of Intrexon, and we commend the work published on the name in a recent Seeking Alpha Commentary. We look forward to reading further commentary on Intrexon, as its businesses are too scattered with partners that Citron believes are not as they appear to be.

Lastly, what has bothered us about Intrexon is while the company has not been shy about going to investment conferences and selling stock offerings, they were never able obtain a smart money biotech shareholder. If they don’t get it, then we don’t get it. We look forward to reading more on the name.

Cautious Investing To All

Mobileye is Worth $11 per Share — Insiders Know It, Goldman Sachs Knows it, Citron Knows it, and Now You Know it!


2016 Price Target (Generous) :

Reduced to $11


Since our first report, Mobileye’s (NASDAQ:MBLY) long-term prospects have gone from bad to worse.  Insiders know it, Goldman Sachs definitely knows it … because at the end of the day,

Money Talks Bullshit Walks

In this report, we detail critical competitive landscape changes since our last report that the market has not priced in yet, but are hiding in plain sight.  Then Citron Research offers up the only intellectually honest way to value Mobileye.

It May Jump but It Will Never Fly.  

For the rest of the story you won’t read anywhere else, CLICK HERE!